摘要
目的：以循证医学的方法对5％咪喹莫特乳膏治疗光化性角化病的疗效与安全性进行系统评价。方法：检索PubMed、Ovid、Web of Science、UMI、elsevier，以及Cochrane图书馆，纳入比较5％咪喹莫特乳膏与安慰剂的随机对照试验，由两名评价者独立提取资料并进行方法学质量评估。试验数据的统计分析采用RevMan4．2．8软件进行。结果：最终纳入5个RCT，对其治疗光化性角化病进行了Meta分析，显示其与对照组相比，差异具有统计学意义，合并后RR=5．82（95％CI，3．44～9．83），没有报道与5％咪喹莫特乳膏临床应用相关的严重系统性不良反应。结论：现有临床证据表明，5％咪喹莫特乳膏治疗光化性角化病有确切的疗效与较好的安全性。
Objective： To evaluate the efficacy and safety of imiquimod 5% cream for actinic keratosis. Methods： PubMed, Ovid, Web of Science, UMI, Elsevier, and Cochrane Library were searched. Randomized controlled trials （RCT） comparing imlquimod 5% cream versus placebo were included. Two reviewers independently performed data extraction and assessed the quality of papers selected. Data were entered and analyzed by RevMan4.2.8 software supplied by the Cochrane Collaboration. Results： Five high quality trials were included. Meta - analysis of the treatment of imiquimod for actinic keratosis showed that the difference of clinical efficacy between imiquimod and placebo was statistically significant, with a combined RR of 5.82 （ 95% CI, 3.44-9.83）. Severe systemic adverse events were not reported. Conclusion： 5% imiquimod cream is an effective and safe medicine for actinic keratosis.
出处
《中国麻风皮肤病杂志》
2006年第11期891-893,共3页
China Journal of Leprosy and Skin Diseases
